01 February 2008

New sex gel to be tested

Researchers dedicated to finding a gel or cream that could work to protect women from Aids say they got permission from Pfizer Inc. to use its newest HIV drug.

Researchers dedicated to finding a gel or cream that could work invisibly to protect women from Aids the way a condom does said on Wednesday they got permission from Pfizer Inc. to use its newest HIV drug.

The International Partnership for Microbicides said Pfizer gave it a royalty-free license to try to develop maraviroc in a cream or gel for the prevention of HIV infection.

Maraviroc, sold under the brand names of Selzentry and Celsentri, is one of a new class of HIV drugs called CCR5 blockers, which prevents the virus from getting into the cells it infects.

Promising new compound
"This agreement adds a promising new compound to IPM's pipeline, allowing us to explore new ways to prevent HIV infection," Dr Zeda Rosenberg, chief executive officer of the group, said in a statement.

Microbicides are products, such as gels or creams, that could be applied vaginally or anally to prevent transmission of the human immunodeficiency virus that causes Aids.

So far, attempts to create a microbicide have failed.

Under this agreement, IPM may develop, manufacture and distribute a maraviroc-based microbicide in developing countries without paying a royalty.

"In addition to developing new drugs to treat Aids, we are committed to searching for ways our drugs can be used to slow down or stop this epidemic," said Pfizer vice President Dr Jack Watters.

33 million infected
The Aids virus infects 33 million people globally, according to the World Health Organization. It has killed 25 million, and there is no vaccine to prevent the fatal and incurable virus.

Condoms can protect men and women, but health experts note that many men refuse to use them. In many countries, a women who demands that her husband or partner use a condom can face refusal or even a beating.

According to the United Nations, in sub-Saharan Africa, almost 61 percent of adults infected with HIV are women.

"Women in the developing world are especially vulnerable to HIV, and urgently need new ways to protect themselves," said Dr Tachi Yamada, president of the Bill & Melinda Gates Foundation's Global Health Programme.

"For Pfizer to offer one of its most important new drugs to benefit the poorest of the poor shows a special act of commitment. I hope their example will point the way for other companies to consider how they can address major global health challenges as well."

The microbicides group also has agreements with Johnson & Johnson subsidiary Tibotec Pharmaceuticals Ltd., Merck & Co., Bristol-Myers Squibb and Gilead Sciences Inc. to develop some of their HIV drugs. – (Reuters Health)

Read more:
HIV/Aids Centre
The gels that may stop HIV

February 2008


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

HIV/Aids expert

Dr Sindisiwe van Zyl qualified at the University of Pretoria before working for an HIV/AIDS NPO in Soweto for many years. She was named one of the Mail & Guardian's Top 200 Young South Africans in 2012.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules